Intralesional Alteplase for Iliopsoas Hematoma in Von Willebrand Disease
Prosperous Treatment of Iliopsoas Hematoma with Alteplase and Drainage
Table of Contents
Published November 2, 2025
Understanding Iliopsoas Hematomas
Iliopsoas hematomas, collections of blood within the iliopsoas muscle (a major hip flexor), are relatively rare but can cause meaningful pain and mobility issues. They often arise from trauma, anticoagulation therapy, or, as in a recent case, underlying bleeding disorders. Prompt diagnosis and treatment are crucial to prevent complications like nerve compression or compartment syndrome.
Case Study: Von Willebrand Disease and Hematoma Resolution
A recent case detailed the successful management of a large iliopsoas hematoma in a patient diagnosed with Von Willebrand disease, a genetic disorder causing impaired blood clotting. The patient presented with a substantial hematoma, prompting a combined treatment approach.
Initial management involved percutaneous drainage – using imaging guidance to insert a drain and remove the accumulated blood. However, due to the hematoma’s size and the patient’s underlying bleeding disorder, complete resolution wasn’t achieved with drainage alone.
The Role of Intralesional Alteplase
To enhance clot breakdown and facilitate drainage,clinicians administered alteplase directly into the hematoma (intralesional administration). Alteplase is a thrombolytic agent, meaning it dissolves blood clots. This adjunctive therapy proved effective in reducing the hematoma’s size and improving the patient’s clinical condition.
The combination of percutaneous drainage and intralesional alteplase allowed for a less invasive approach than surgical intervention, minimizing potential morbidity. The patient experienced a positive outcome, demonstrating the potential benefits of this combined strategy.
Implications for Clinical Practice
This case highlights the potential value of considering intralesional alteplase as an adjunct to percutaneous drainage in managing large iliopsoas hematomas, notably in patients with underlying coagulopathies like Von Willebrand disease. While further research is needed, this approach offers a promising alternative to more aggressive surgical options. Careful patient selection and monitoring are essential when utilizing thrombolytic therapy.